Neoplasms

All Conditions

Skin and Connective Tissue Diseases

Digestive System Diseases

Gland and Hormone Related Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Nervous System Diseases

Respiratory Tract (Lung and Bronchial) Diseases

Blood and Lymph Conditions

Immune System Diseases

Infections

Symptoms and General Pathology

Rare Diseases

Carcinoma

Breast Neoplasms

Pancreatic Neoplasms

Prostatic Neoplasms

Thyroid Neoplasms

Thyroid Diseases

Brain Neoplasms

Carcinoma, Squamous Cell

Sarcoma

Carcinoma, Renal Cell

Lung Neoplasms

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Lymphoma

Liver Neoplasms

Hodgkin Disease

Central Nervous System Neoplasms

Sarcoma, Kaposi

Kidney Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Male Urogenital Diseases

Neoplasms by Histologic Type

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Neoplasms, Connective and Soft Tissue

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Communicable Diseases

Herpesviridae Infections

Virus Diseases

DNA Virus Infections

Neoplasms, Vascular Tissue

Urologic Neoplasms

Kidney Diseases

Urologic Diseases

Nervous System Neoplasms

Brain Diseases

Central Nervous System Diseases

Pancreatic Cancer

Ovarian Cancer

Renal Cell Carcinoma

Ovarian Epithelial Cancer

Soft Tissue Sarcoma

Lymphosarcoma

Hodgkin Lymphoma

Kaposi Sarcoma

The study will use a dual 1H-31P surface coil pair obtained from IGG Medical Advances, Milwaukee, WI. The coil pair consists of a fixed, 12 cm square 31P resonator co-mounted with a flexible two-loop proton coil. The P.I. and colleagues have used this device for approximately 10 years with no apparent ill effects

Proton-decoupled 31P MRS at 1.5T

The study will use surface coils manufactured by commercial vendors. The pulse sequence programs to be used will be monitored automatically by the scanner to insure that SAR limits are not exceeded.

1H Spectroscopy at 1.5T and 3T

Jason Koutcher, MD, PhD

The purpose of this study is to obtain chemical information from part of your body without a biopsy. This is done using a technique called magnetic resonance spectroscopy (MRS) which is similar to magnetic resonance imaging (MRI) except that signals are detected from the chemicals (spectroscopy) naturally present in your body using radio waves. To receive this information from your body, small loops of wire (surface coils), placed near the tissue of interest, may be used to more effectively detect signals that come from the chemicals in your body. The investigators may use a second radio channel simultaneously, which will allow us to obtain greater chemical information (decoupling). The results may also help us to understand how this study can be used to help other patients with your condition.

The investigators propose to use 1H spectroscopy or 1H decoupled 31P NMR spectroscopy to obtain biochemical information about tumor metabolism in patients, both before and after antineoplastic therapy. In healthy volunteers, normal tissue metabolism will also be studied. It is hypothesized that metabolic information may be of prognostic significance, or may be useful for timing of therapy.

Spectroscopy With Surface Coils and Decoupling

Columbia University

University of Pennsylvania

St. George's Hospital, London

Royal Marsden NHS Foundation Trust

University Medical Center Nijmegen

Weill Medical College of Cornell University

Memorial Sloan Kettering Cancer Center

Hypoxia

Uterine Cervical Neoplasms

Uterine Neoplasms

Genital Neoplasms, Female

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Micronutrients

Anti-Infective Agents

All Drugs and Chemicals

Iodine

Cadexomer iodine

Patients will receive 124IAZGP(124I-Iodo-Azomycin Galacto-Pyranoside).

You will receive the radioactive tracer through an injection in your vein. Blood (about 5 tablespoons in all) will be taken after the radioactive tracer has been given. Over the course of study day 1, bloods will be drawn 8 times and then 4 more times on study day 2. You will undergo three \*IAZGP PET scans, one shortly after you receive the injection, one later the same day and one the following day. Each scan will take about an hour. This means you would be asked to come back 2 days in a row.

124I-Iodo-Azomycin Galacto-Pyranoside

Heiko Schöder, MD

The purpose of this study is to evaluate low oxygen areas called hypoxia within the tumor. These low oxygen areas are thought to be the reason why tumors are more resistant to radiation treatment. A tracer is an extremely small quantity of a substance. Tracer to which radioactivity has been attached may be used to "trace" events in the body. A tracer called iodo-azomycin galactopyranoside (or \*IAZGP) appears to be able to detect low oxygen areas within tumor.

Radioactive iodine in this molecule can be detected by an imaging technique called a PET scan. This present study involves obtaining three scans using this new imaging technique. The goal of carrying out many scans is to determine which scan will best show any areas in your tumor that may have low levels of oxygen.

Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors

National Cancer Institute (NCI)

Eye Diseases

Ear, Nose, and Throat Diseases

Esophageal Neoplasms

Urinary Bladder Neoplasms

Chronic Pain

Pain

Head and Neck Neoplasms

Eye Neoplasms

Otorhinolaryngologic Neoplasms

Neurologic Manifestations

Otorhinolaryngologic Diseases

Esophageal Cancer

Chronic Graft Versus Host Disease

Analgesics

Antitussive Agents

Central Nervous System Depressants

Respiratory System Agents

Anti-Obesity Agents

Vasoconstrictor Agents

Methadone

Analgesics, Opioid

D-methadone

Narcotics

Phenylpropanolamine

Guaifenesin

Chlorpheniramine, phenylpropanolamine drug combination

Analgesics, Non-Narcotic

This is an open label dose-ranging trial. The first cohort of 8 patients will receive 40mg of d-methadone every 12 hours.

patients receiving around the clock opioid therapy-No patients were accrued to this group

patients not receiving around the clock opioid therapy.No patients were accrued to this group

8 subjects to receive 40 mg d-Methadone twice a day

d-Methadone

After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.

placebo

Natalie Moryl, MD

The purpose of this study is to determine the safest dose of d-methadone that can be given, without causing severe side effects in most patients with chronic pain. Patients are being asked to participate in the Phase I portion of this study.

Study of D-Methadone in Patients With Chronic Pain

A Phase I/II Study of D-Methadone in Patients With Chronic Pain

The number of patients who reached a safe and well tolerated dose of d-methadone

Patients Receiving D-methadone 40 mg

Age, Categorical

Sex: Female, Male

Dr. Natalia Moryl

oral d-methadone 40 mg

d-Methadone: 8 subjects to receive 40 mg d-Methadone twice a day

Phase I, Cohort l

Number Who Reached a Safe Dose

Overall Study

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Spectroscopy With Surface Coils and Decoupling	NCT00581815	Adrenal Cortica... Brain Cancer Breast Cancer CNS Cancer Colon Cancer HEENT Cancer Hodgkin's Disea... Kaposi's Sarcom... Liver Cancer Lung Cancer Non-Hodgkin's L... Ovarian Cancer Pancreatic Canc... Prostate Cancer Rectal Cancer Renal Cancer Sarcoma Squamous Cell C... Thyroid Cancer	Proton-decouple... 1H Spectroscopy...	18 Years -	Memorial Sloan Kettering Cancer Center
Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors	NCT00588276	Cervical Cancer HEENT Cancer Renal Cancer Uterine Cancer CERVIX UTERI NO... RECTUM	124I-Iodo-Azomy...	18 Years -	Memorial Sloan Kettering Cancer Center
Study of D-Methadone in Patients With Chronic Pain	NCT00588640	Pain Bladder Cancer Breast Cancer CNS Cancer Colon Cancer Esophageal Canc... Pancreatic Canc... Prostate Cancer Uterine Cancer Head and Neck C... Eye Cancer Otorhinolaryngo...	d-Methadone D-methadone placebo	18 Years -	Memorial Sloan Kettering Cancer Center
Study of D-Methadone in Patients With Chronic Pain	NCT00588640	Pain Bladder Cancer Breast Cancer CNS Cancer Colon Cancer Esophageal Canc... Pancreatic Canc... Prostate Cancer Uterine Cancer Head and Neck C... Eye Cancer Otorhinolaryngo...	d-Methadone D-methadone placebo	18 Years -	Memorial Sloan Kettering Cancer Center
Study of D-Methadone in Patients With Chronic Pain	NCT00588640	Pain Bladder Cancer Breast Cancer CNS Cancer Colon Cancer Esophageal Canc... Pancreatic Canc... Prostate Cancer Uterine Cancer Head and Neck C... Eye Cancer Otorhinolaryngo...	d-Methadone D-methadone placebo	18 Years -	Memorial Sloan Kettering Cancer Center
Spectroscopy With Surface Coils and Decoupling	NCT00581815	Adrenal Cortica... Brain Cancer Breast Cancer CNS Cancer Colon Cancer HEENT Cancer Hodgkin's Disea... Kaposi's Sarcom... Liver Cancer Lung Cancer Non-Hodgkin's L... Ovarian Cancer Pancreatic Canc... Prostate Cancer Rectal Cancer Renal Cancer Sarcoma Squamous Cell C... Thyroid Cancer	Proton-decouple... 1H Spectroscopy...	18 Years -	Memorial Sloan Kettering Cancer Center

Spots Global Cancer Trial Database for heent cancer

Every month we try and update this database with for heent cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.